Publications by authors named "E Wiltshire"
Aims: This study aimed to identify key factors with the greatest influence on glycaemic outcomes in young individuals with type 1 diabetes (T1D) and very elevated glycaemia after 3 months of automated insulin delivery (AID).
Materials And Methods: Data were combined and analysed from two separate and previously published studies with similar inclusion criteria assessing AID (MiniMed 780G) efficacy among young individuals naïve to AID (aged 7-25 years) with glycated haemoglobin A1c (HbA1c) ≥69 mmol/mol (≥8.5%).
Aim: To investigate extension phase outcomes with intermittently scanned continuous glucose monitoring (isCGM 2.0) in children with type 1 diabetes mellitus (T1DM) and elevated HbA (7.5-12.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to explore the experiences of adolescents and young adults (ages 13-25) with chronic high glucose levels who switched from multiple daily injections (MDI) to advanced hybrid closed-loop (AHCL) therapy.
- Researchers conducted semi-structured interviews with 14 participants after three months on the AHCL, identifying three key themes: improved glucose levels enhanced overall health perceptions, AHCL features supported self-management, and insulin delivery automation reduced care burden.
- The transition to AHCL therapy resulted in positive impacts on physical, mental, and social well-being, although some participants experienced transient pseudo-hypoglycaemia, highlighting the need for individualized support to facilitate uptake.
Background: Automated insulin delivery is the treatment of choice in adults with type 1 diabetes. Data are needed on the efficacy and safety of automated insulin delivery for children and youth with diabetes and elevated glycated hemoglobin levels.
Methods: In this multicenter, open-label randomized controlled trial, we assigned patients with type 1 diabetes in a 1:1 ratio either to use an automated insulin delivery system (MiniMed 780G) or to receive usual diabetes care of multiple daily injections or non--automated pump therapy (control).
Aim: We investigated if continuous glucose monitoring (CGM) in children with type 1 diabetes (T1D) within 12 months of being diagnosed modifies the development of glycaemic outcome inequity on the basis of either ethnicity or socio-economic status (SES).
Method: De-identified clinical and SES data from the KIWIDIAB data network were collected 12 months after diagnosis in children under 15 years diagnosed with T1D between 1 October 2020 and 1 October 2021.
Results: There were 206 children with new onset T1D: CGM use was 56.